What went wrong in the natalizumab trials?

Lancet

Volumn 367, Issue 9512, 2006, Pages 708-710

  Langer Gould, Annette ^a   Steinman, Lawrence ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 INTERFERON; NATALIZUMAB;

CLINICAL TRIAL; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DRUG FATALITY; DRUG SAFETY; HUMAN; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE;

EID: 33644643350     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68279-2     Document Type: Note

References (22)

1. BK Kleinschmidt-DeMasters, KL Tyler Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis N Engl J Med 353 2005 369 374
2. A Langer-Gould, SW Atlas, AJ Green, AW Bollen, D Pelletier Progressive multifocal leukoencephalopathy in a patient treated with natalizumab N Engl J Med 353 2005 375 381
3. G Van Assche, M van Ranst, R Sciot Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease N Engl J Med 353 2005 362 368
4. CM Poser, DW Paty, L Scheinberg New diagnostic criteria for multiple sclerosis: guidelines for research protocols Ann Neurol 13 1983 227 231
5. GA Schumacker, G Beebe, RF Kibler Problems of experimental trials of therapy in multiple sclerosis Ann N Y Acad Sci 122 1965 552 568
6. WI McDonald, A Compston, G Edan Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis Ann Neurol 50 2001 121 127
7. Bryan WW. Clinical Review; BLA 125104/0; Tysabri (natalizumab). Washington, DC: Food and Drug Administration, March 8, 2005: 37.
8. A Achiron, Y Barak, Z Rotstein Longitudinal disability curves for predicting the course of relapsing-remitting multiple sclerosis Mult Scler 9 2003 486 491
9. M Eriksson, O Andersen, B Runmarker Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis Mult Scler 9 2003 260 274
10. B Runmarker, O Andersen Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up Brain 116 1993 117 134
11. BG Weinshenker, B Bass, GP Rice The natural history of multiple sclerosis: a geographically based study. I: clinical course and disability Brain 112 1989 133 146
12. SJ Pittock, WT Mayr, RL McClelland Change in MS-related disability in a population-based cohort: a 10-year follow-up study Neurology 62 2004 51 59
13. KM Myhr, T Riise, C Vedeler Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension Mult Scler 7 2001 59 65
14. O Kantarci, A Siva, M Eraksoy Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG) Neurology 51 1998 765 772
15. MP Amato, G Ponziani, ML Bartolozzi, G Siracusa A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials J Neurol Sci 168 1999 96 106
16. WC Black, HG Welch Screening for disease AJR Am J Roentgenol 168 1997 3 11
17. LA Pompeii, SD Moon, DC McCrory Measures of physical and cognitive function and work status among individuals with multiple sclerosis: a review of the literature J Occup Rehabil 15 2005 69 84
18. SG Lynch, BA Parmenter, DR Denney The association between cognitive impairment and physical disability in multiple sclerosis Mult Scler 11 2005 469 476
19. M Trojano, C Avolio, C Manzari Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events J Neurol Neurosurg Psychiatry 58 1995 300 306
20. R Bergamaschi, C Berzuini, A Romani, V Cosi Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis J Neurol Sci 189 2001 13 21
21. C Confavreux, S Vukusic, P Adeleine Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process Brain 126 2003 770 782
22. US Food and Drug Administration, Center for Drug Evaluation and Research Questions and answers on Tysabri (natalizumab) regarding the lifting of the clinical hold http://www.fda.gov/cder/drug/infopage/natalizumab_clinicalhold_ga. htm Feb 15, 2006 accessed Feb 27, 2006